$IGNG News Out!! Imaging3 Announces Additio
Post# of 85452
(Total Views: 264)
Posted On: 01/30/2018 6:04:41 AM
$IGNG News Out!!
Imaging3 Announces Addition of Dr. Douglas Beall to the Scientific Advisory Board
Mon, 22 Jan 2018 14:30 GMT | GlobeNewswire | Symbol: IGNG
BURBANK, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Imaging3, Inc. (OTCQB:IGNG), is pleased to announce the addition of Dr. Douglas Beall to the newly formed Scientific Advisory Board (SAB).
“As we continue along the path to commercialization, we are recruiting industry leaders who bring timely insights about how our technology can be improved for both patients and practitioners. Having in-house, experienced feedback from industry veterans at this stage is incredibly valuable to our organization,” said CEO, John Hollister.
Dr. Douglas P. Beall, board certified in both radiology and pain management, is the chief of services at the Clinical Radiology of Oklahoma, Oklahoma City. He also serves as adjunct faculty in the Department of Orthopedics, Bone and Joint Hospital at St. Anthony Orthopedic Residency Program in Oklahoma City. Prior to entering the private sector, Dr. Beall served in a variety of important roles in the United States Air Force. Dr. Beall has authored numerous publications, many in the area of imaging, as well as conducted clinical studies. He also serves and has consulted with a variety of early stage and commercial companies. Dr. Beall received his BS from Oklahoma State University and an MD from Georgetown University. He completed a translational internship at the University of Oklahoma, residency in diagnostic radiology at The Johns Hopkins Hospital and fellowship in musculoskeletal radiology at the Mayo Clinic.
Dr. Beall stated, “This technology has the potential to be one of the most exciting imaging innovations in the past 20 years, with the potential to help many patients both in the United States and abroad.”
About Imaging3, Inc.
Imaging3, Inc., founded in 1993, has developed a patented medical imaging technology, called the Dominion SmartScan™, that will produce 3D x-ray images, virtually in real time. The SmartScan technology has the potential to allow healthcare professionals to perform diagnostic and therapeutic procedures more quickly and accurately, resulting in higher throughput for the clinicians and fewer safety risks for the patient. In addition, Imaging3’s technology exposes patients to significantly less harmful radiation than current imaging technologies such as CT scans, which the company believes will allow scans to be used in many settings where there are concerns about radiation exposure. The technology also allows for greater portability, easier installation, and a significantly reduced cost burden for the healthcare system overall. Imaging3 is planning to submit a 510K application to the FDA during 2018 in order to gain marketing authorization for the SmartScan technology.
Visit the company’s website at http://www.imaging3.com for detailed information about the company’s technology.
Safe Harbor Statement
Imaging3 cautions you that any statement included in this press release that is not a description of historical facts is a forward-looking statement. Many of these forward-looking statements contain the words "anticipate," "believe," "estimate," "may" "intend," "expect" and similar expressions. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the company and are subject to a number of risks and uncertainties inherent in the Imaging3’s business, including, without limitation: the company may not ever obtain FDA approval for any of its devices; the company may not be able to secure the funds necessary to support its product development plans; and the company may not ever achieve the market success to sustain a profitable business. In addition, there are risks and uncertainties related to economic recession or terrorist actions, competition from much larger imaging companies, technological obsolescence, unexpected costs and delays, potential product liability claims, and many other factors. More detailed information about Imaging3 and the risk factors that may affect the realization of forward-looking statements is set forth in the company’s filings with the Securities and Exchange Commission, including the company’s Annual Report on Form 10-K and its Quarterly Report on Form 10-Q. Such documents may be read free of charge on the SEC’s website at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Imaging3 undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Investor Relations Contact:
John Hollister
Chief Executive Officer
info@imaging3.com
Imaging3 Announces Addition of Dr. Douglas Beall to the Scientific Advisory Board
Mon, 22 Jan 2018 14:30 GMT | GlobeNewswire | Symbol: IGNG
BURBANK, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Imaging3, Inc. (OTCQB:IGNG), is pleased to announce the addition of Dr. Douglas Beall to the newly formed Scientific Advisory Board (SAB).
“As we continue along the path to commercialization, we are recruiting industry leaders who bring timely insights about how our technology can be improved for both patients and practitioners. Having in-house, experienced feedback from industry veterans at this stage is incredibly valuable to our organization,” said CEO, John Hollister.
Dr. Douglas P. Beall, board certified in both radiology and pain management, is the chief of services at the Clinical Radiology of Oklahoma, Oklahoma City. He also serves as adjunct faculty in the Department of Orthopedics, Bone and Joint Hospital at St. Anthony Orthopedic Residency Program in Oklahoma City. Prior to entering the private sector, Dr. Beall served in a variety of important roles in the United States Air Force. Dr. Beall has authored numerous publications, many in the area of imaging, as well as conducted clinical studies. He also serves and has consulted with a variety of early stage and commercial companies. Dr. Beall received his BS from Oklahoma State University and an MD from Georgetown University. He completed a translational internship at the University of Oklahoma, residency in diagnostic radiology at The Johns Hopkins Hospital and fellowship in musculoskeletal radiology at the Mayo Clinic.
Dr. Beall stated, “This technology has the potential to be one of the most exciting imaging innovations in the past 20 years, with the potential to help many patients both in the United States and abroad.”
About Imaging3, Inc.
Imaging3, Inc., founded in 1993, has developed a patented medical imaging technology, called the Dominion SmartScan™, that will produce 3D x-ray images, virtually in real time. The SmartScan technology has the potential to allow healthcare professionals to perform diagnostic and therapeutic procedures more quickly and accurately, resulting in higher throughput for the clinicians and fewer safety risks for the patient. In addition, Imaging3’s technology exposes patients to significantly less harmful radiation than current imaging technologies such as CT scans, which the company believes will allow scans to be used in many settings where there are concerns about radiation exposure. The technology also allows for greater portability, easier installation, and a significantly reduced cost burden for the healthcare system overall. Imaging3 is planning to submit a 510K application to the FDA during 2018 in order to gain marketing authorization for the SmartScan technology.
Visit the company’s website at http://www.imaging3.com for detailed information about the company’s technology.
Safe Harbor Statement
Imaging3 cautions you that any statement included in this press release that is not a description of historical facts is a forward-looking statement. Many of these forward-looking statements contain the words "anticipate," "believe," "estimate," "may" "intend," "expect" and similar expressions. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the company and are subject to a number of risks and uncertainties inherent in the Imaging3’s business, including, without limitation: the company may not ever obtain FDA approval for any of its devices; the company may not be able to secure the funds necessary to support its product development plans; and the company may not ever achieve the market success to sustain a profitable business. In addition, there are risks and uncertainties related to economic recession or terrorist actions, competition from much larger imaging companies, technological obsolescence, unexpected costs and delays, potential product liability claims, and many other factors. More detailed information about Imaging3 and the risk factors that may affect the realization of forward-looking statements is set forth in the company’s filings with the Securities and Exchange Commission, including the company’s Annual Report on Form 10-K and its Quarterly Report on Form 10-Q. Such documents may be read free of charge on the SEC’s website at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Imaging3 undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Investor Relations Contact:
John Hollister
Chief Executive Officer
info@imaging3.com
(0)
(0)